The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | An insight into novel measures being explored for the diagnosis of cardiac amyloidosis
Faizi Jamal, MD, City of Hope, Duarte, CA, discusses the novel measures being explored for the diagnosis of cardiac amyloidosis. In nuclear medicine, work is being conducted to identify radioisotopes specific to amyloid proteins such as light chain (AL) or transthyretin (TTR). Cardiac MRI may become an increasingly useful diagnostic tool in cardiac amyloidosis, using late gadolinium enhancement (LGE), extracellular volume (ECV), T1, and T2 as measures of function. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research supported by an award from Johnson & Johnson Innovation, LLC.
